Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01BGW
|
||||
| Former ID |
DNC006058
|
||||
| Drug Name |
(2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine
|
||||
| Synonyms |
(S)-2-(6-methoxyindazol-1-yl)-1-methylethylamine
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
CC(CN1C2=C(C=CC(=C2)OC)C=N1)N
|
||||
| InChI |
1S/C11H15N3O/c1-8(12)7-14-11-5-10(15-2)4-3-9(11)6-13-14/h3-6,8H,7,12H2,1-2H3/t8-/m0/s1
|
||||
| InChIKey |
WSEWULCWBQDNEH-QMMMGPOBSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2B receptor | Target Info | Inhibitor | [2] | |
| 5-hydroxytryptamine 2A receptor | Target Info | Inhibitor | [2] | ||
| 5-hydroxytryptamine 2C receptor | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channelshsa04020:Calcium signaling pathway | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (q) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling | |||||
| SIDS Susceptibility Pathways | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. Epub 2007 Nov 4.Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists. | ||||
| REF 2 | J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.